Dual Probes for Positron Emission Tomography (PET) and Fluorescence Imaging (FI) of Cancer
Dual probes that possess positron emission tomography (PET) and fluorescence imaging (FI) capabilities are precision medicine tools that can be used to improve patient care and outcomes. Detecting tumor lesions using PET, an extremely sensitive technique, coupled with fluorescence-guided surgical re...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_8fda49e411384be28a0ff63d6eb24c3c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Richard Yuen |e author |
| 700 | 1 | 0 | |a Frederick G. West |e author |
| 700 | 1 | 0 | |a Frank Wuest |e author |
| 245 | 0 | 0 | |a Dual Probes for Positron Emission Tomography (PET) and Fluorescence Imaging (FI) of Cancer |
| 260 | |b MDPI AG, |c 2022-03-01T00:00:00Z. | ||
| 500 | |a 10.3390/pharmaceutics14030645 | ||
| 500 | |a 1999-4923 | ||
| 520 | |a Dual probes that possess positron emission tomography (PET) and fluorescence imaging (FI) capabilities are precision medicine tools that can be used to improve patient care and outcomes. Detecting tumor lesions using PET, an extremely sensitive technique, coupled with fluorescence-guided surgical resection of said tumor lesions can maximize the removal of cancerous tissue. The development of novel molecular probes is important for targeting different biomarkers as every individual case of cancer has different characteristics. This short review will discuss some aspects of dual PET/FI probes and explore the recently reported examples. | ||
| 546 | |a EN | ||
| 690 | |a cancer imaging | ||
| 690 | |a dual probes | ||
| 690 | |a fluorescence | ||
| 690 | |a positron emission tomography | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmaceutics, Vol 14, Iss 3, p 645 (2022) | |
| 787 | 0 | |n https://www.mdpi.com/1999-4923/14/3/645 | |
| 787 | 0 | |n https://doaj.org/toc/1999-4923 | |
| 856 | 4 | 1 | |u https://doaj.org/article/8fda49e411384be28a0ff63d6eb24c3c |z Connect to this object online. |